I read a lot of GLP-1 research so you don’t have to, and 2026 has been a genuinely weird year for this drug class — real wins, a real flop, and a lawsuit pile that’s growing fast. Here’s the roundup, no spin.

THE GOOD

Heart failure: A large real-world study found starting a GLP-1 cut hospitalization or death from heart failure with preserved ejection fraction (HFpEF) by roughly 40% overall — 42% for semaglutide, 58% for tirzepatide, compared to a standard diabetes drug. That’s a big enough signal that the FDA added heart-failure outcome data to the prescribing information this year.

Addiction: This one surprised even researchers. A Lancet-published randomized trial found semaglutide reduced heavy drinking days in people with alcohol use disorder. Separately, a large study of veterans found GLP-1 users had lower rates of alcohol, opioid, and nicotine use disorder. Nobody fully understands the mechanism yet, but the drugs seem to turn down cravings generally, not just food cravings.

Suicide risk — actually good news for once: Remember the suicidal-ideation warning that got attached to these drugs a few years back? In January 2026, the FDA said it’s moving to remove that warning from semaglutide, tirzepatide, and liraglutide labels, based on a meta-analysis covering 91 trials and nearly 108,000 patients, plus a separate claims study comparing over 2 million people. No increased risk found. That’s a real reversal, and it doesn’t get nearly the coverage the original scare did.

THE NOT-SO-GOOD

Alzheimer’s —The Not the outcome we were hoping for: But that is why we do research.
Novo Nordisk’s EVOKE and EVOKE+ trials tested oral semaglutide in people with early Alzheimer’s. It did not show a cognitive benefit versus placebo. This was a genuinely big, well-run trial, and it just didn’t pan out. If you saw hype about GLP-1s as a dementia treatment, file that under “not yet, maybe not ever.”

Muscle loss: A preprint (meaning not yet peer-reviewed — treat it as early data) looked at roughly 670,000 GLP-1 users and found tirzepatide caused more lean muscle mass loss than semaglutide, with about 1 in 10 tirzepatide users hitting a pattern researchers called a “depletive metabotype” — losing more than 20% of body weight while losing more than 5% lean mass. This is exactly why every doctor keeps telling you to lift weights and eat your protein while you’re on these drugs. It’s not optional.

Litigation: As of August 2026, there are nearly 4,000 lawsuits consolidated against Novo Nordisk and Eli Lilly, up almost 200% since January 2025. Most allege gastroparesis (stomach paralysis), with smaller numbers citing bowel blockage or gallbladder problems. A separate, newer batch of cases focused on a vision condition called NAION is still working through the evidence stage — the vision risk itself is genuinely unresolved in the research, not just in the courtroom. Bellwether trials are expected late this year. No settlements yet.

None of this is medical advice, and none of it means “don’t take these drugs” — I’m on tirzepatide myself and I’m not stopping over a preprint or a pending lawsuit. It does mean: talk to your doctor about your specific risk factors, get your labs and body composition checked periodically, and don’t let a scary headline (or an overly rosy one) make the decision for you instead of your doctor.

I keep a running list of research updates like this for my own tracking — some of it’s in the book, and I’ll keep posting updates here as new studies land.

Sources

• AJMC, “GLP-1s Reduced Adverse Heart Failure Events by 40% in Patients With HFpEF,” 2026.
• Medscape, heart-failure data added to GLP-1 prescribing information, 2026.
• The Lancet, randomized trial of semaglutide for alcohol use disorder, 2026.
• NBC News, GLP-1s and substance use disorder (veterans study), 2026.
• FDA.gov, update on suicidality evaluation for GLP-1 receptor agonists / Pharmacy Times coverage, Jan. 2026.
• Clinical Trials Arena, AD/PD 2026 coverage of Novo Nordisk EVOKE/EVOKE+ Alzheimer’s trial results.
• medRxiv (preprint, not peer-reviewed), tirzepatide vs. semaglutide lean mass loss, April 2026.
• mdlupdate.com, GLP-1 receptor agonist multidistrict litigation status, Aug. 2026.

If you’ve been following discussions about the Medicare GLP-1 Bridge program, you’ve probably noticed a pattern: a large number of people are reporting denials, especially those who have sleep apnea.

This is not a coincidence. It is the result of a clear rule set by the Centers for Medicare & Medicaid Services (CMS).

The Official Rule

According to CMS, people who have a diagnosis of moderate-to-severe obstructive sleep apnea (OSA) are not eligible for the Medicare GLP-1 Bridge program.

Here’s why:

• The Bridge program is only for people seeking GLP-1 medications (such as Zepbound KwikPen, Wegovy, or Foundayo) purely for weight management.
• Moderate-to-severe sleep apnea is already considered a covered indication under regular Medicare Part D.
• Zepbound has an FDA-approved indication specifically for moderate-to-severe obstructive sleep apnea in adults with obesity.
• Because of this, CMS requires that anyone with this diagnosis go through their regular Part D plan instead of the Bridge program.

If a doctor submits a prior authorization to the Bridge program and the patient has an OSA diagnosis on record, the request will be denied.

Other Common Reasons for Denial

While sleep apnea is one of the biggest triggers, it is not the only reason people are being turned down. Other frequent denial reasons include:

• Having Type 2 diabetes
• Having noncirrhotic MASH (a form of fatty liver disease)
• Already receiving a GLP-1 medication through a Part D plan
• Not meeting the BMI requirements at the time GLP-1 therapy was started
• Being prescribed a form of Zepbound that is not covered (only the KwikPen is allowed under the Bridge)
• Incomplete prior authorization paperwork

What to Do If You Are Denied (Appeal Process)

This is an important point that many people do not realize:

The Medicare GLP-1 Bridge program currently does not have a formal appeals process.

Unlike regular Medicare Part D denials (which have multiple levels of appeal), CMS has stated that there is no standard appeal pathway for Bridge program denials at this time.

What you can do:

1. Resubmit the prior authorization
   If the denial was caused by missing or incorrect information, your doctor can correct the paperwork and resubmit it.
2. Review the exact denial reason
   Both you and your doctor should receive a denial letter. Read it carefully. Many denials happen because the wrong pathway was used (for example, submitting to the Bridge when the patient has sleep apnea).
3. Switch pathways if needed
   • If you have moderate-to-severe sleep apnea → Try submitting through your regular Part D plan using the sleep apnea indication.
   • If you do not have a Part D-covered diagnosis → Work with your doctor to fix any documentation problems and resubmit to the Bridge.
4. Contact the Bridge Call Center
   Prescribers can call the Medicare GLP-1 Bridge Call Center at 855-273-0102 (Monday–Friday, 8 a.m. – 7 p.m. ET) for questions about a specific prior authorization.

Can New Information Help After a Past Sleep Apnea Diagnosis?

Some people were diagnosed with obstructive sleep apnea (OSA) years ago but believe their condition has improved. In these cases, a few readers have asked whether updated information — such as overnight oxygen saturation (SpO2) readings from a fitness tracker — can make a difference.

While consumer devices like Garmin watches can track SpO2 trends during sleep and may show consistently normal oxygen levels, they are not considered a formal medical diagnosis. Medicare and the Bridge program generally require official clinical documentation, such as a recent sleep study or an updated evaluation from your doctor.

If you previously had an OSA diagnosis but believe it is no longer accurate, the most useful step is to:

• Discuss your current symptoms (or lack of symptoms) with your doctor
• Share any overnight SpO2 data you have collected
• Ask whether a new sleep study or updated clinical note is appropriate

Your doctor can then decide whether the older OSA diagnosis should still be listed on a Bridge program application or whether the case should instead be submitted through regular Part D using a different indication.

Final Thoughts:

The Medicare GLP-1 Bridge program has helped many seniors gain access to these medications at a lower cost. However, it was never designed for everyone. CMS intentionally excluded people with certain diagnoses, including moderate-to-severe sleep apnea, so those cases would stay under the normal Part D system.

If you were denied, the first and most important step is to understand the exact reason. In many cases, the solution is not an “appeal” but using the correct coverage pathway or correcting the original submission.